In contrast, a regimen of intermittent enzyme replacement therapy dosing with rhb-Gal, followed by enzyme withdrawal, is sufficient to augment b-Gal activity levels in GM1 gangliosidosis patient fibroblasts and in a mouse model of GM1 gangliosidosis without promoting NEU1 deficiency (40). The gene discussed is GAL; the disease is GM1 gangliosidosis.